JTV-161 is under clinical development by Japan Tobacco and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JTV-161’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JTV-161 overview
JTV-161 is under the development for the treatment of pulmonary arterial hypertension. The therapeutic candidate is administered through oral route. It acts by targeting PIM 1 (serine/threonine protein kinase pim 1).
Japan Tobacco overview
Japan Tobacco (JT Group) is a manufacturer of cigarettes. The company also manufactures, markets, and sells varied pharmaceutical and processed food products such as frozen cooked rice and noodles, instant noodles, bread, and frozen bread, packaged cooked rice, bakery goods, yeast extracts and seasoning, prescription drugs, and generic drugs. JT Group distributes its products through supermarkets, street and train station kiosks, convenience stores, small independent retailers, and vending machines. It caters to retail, industrial and commercial customers in Europe, Africa, the Middle East, Asia-Pacific, and the Americas, and other regions. JT Group is headquartered in Minato-Ku, Tokyo, Japan.
For a complete picture of JTV-161’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
